Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765765 · ClinicalTrials.gov registry record · Phase 1
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by University of Medicine and Dentistry of New Jersey.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00765765 is a Phase 1 study that was terminated before completion, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 6 participants.
The verdict
NCT00765765, a Phase 1 study, was terminated before completion, sponsored by University of Medicine and Dentistry of New Jersey.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Hydroxychloroquine may help ixabepilone work better by making tumor cells more sensitive to the drug. PURPOSE: This phase I/II trial is studying the side effects and best dose of ixabepilone given together with hydroxychloroquine and to see how well they work in treating patients with metastatic breast cancer.
Interventions
- DRUG ixabepilone
- DRUG hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00765765
The ClinicalTrials.gov registry entry for NCT00765765 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Medicine and Dentistry of New Jersey, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ixabepilone is the first listed.
NCT00765765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00765765 about?
NCT00765765 is a clinical study titled "Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Hydroxychloroquine may help ixabepilone work better by making tumor cells more sensitive to the drug. PURPOSE: This ph...
What is the current status of trial NCT00765765?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2009-02. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00765765?
The interventions under investigation include: ixabepilone (DRUG), hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT00765765?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.